Avaliação do efeito do ácido gálico no tratamento de células de hepatocarcinoma HEPG2 [PDF]
Hepatocellular Carcinoma is the most prevalent primary tiver tumor and is among the top ten cancers that affect the world population. lts development is related, in most cases, the existente of chronic tiver injury, such as occurs in cirrhosis.
Lima, Kelly Goulart
core
Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review. [PDF]
Barbosa EC +8 more
europepmc +1 more source
Rolul sistemului imun și a imunoterapiei în limfoamele Non – Hodgkin.
nticorpii monoclonali stimulează sistemul natural de apărare a organismului pentru a ataca în mod specific celulele afectate de limfom non-Hodgkin. Anticorpii monoclonali sunt o prezenţă obișnuită în organism al dumneavoastră, drept parte componentă a ...
Aliona Nicorici
doaj
Navigating the Multidimensional Impact of Living with Hidradenitis Suppurativa: An In-Depth Netnographic Study on Social Media Platforms. [PDF]
Bellei EA +11 more
europepmc +1 more source
Severe sepsis remains associated with high morbidity and mortality rates, so that new threrapeutics modalities must be sought. The release of various mediators (cytokines, platelet activating factor, oxygen free radicals etc.) of sepsis can be initiated by a variety of stimuli.
openaire +1 more source
Fluoroquinolone and beta-lactam antimicrobials induce different transcriptome profiles in Salmonella enterica persister cells. [PDF]
Mattiello SP +4 more
europepmc +1 more source
Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil. [PDF]
Rivitti-Machado MC +6 more
europepmc +1 more source
F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project. [PDF]
Labarque V +5 more
europepmc +1 more source
Neurologic adverse events of cancer immunotherapy. [PDF]
Brito MH.
europepmc +1 more source

